AIkido Pharma Inc (AIKI)

[F4Xinvestor]

Unfortunately we're still stuck with the scumbag.

[keekee]

Especially for a band of MARKET MAKERS (AIKI MMs) that I have not credited with any intelligence other than that accustomed with a first grader!!!

[keekee]

Frankly baffled at the new smartness. I guess after several losses following me around, gapping holes in their pockets teach them some manners. Still waiting....

[keekee]

Strange that the DUMB, CLUELESS MARKET MAKERS here are not taking my bait to sell lower....who gave these fools some brain?????

[keekee]

I kept waiting for them to return the stock to $0.60, but IDIOTS just commit fraud by fake-selling to themselves. 1934 Act...still in vogue!!!

[keekee]

I see the IDIOTS playing and following me all over my new positions and I just crack up and human STUPIDITY. Fools losing tons of money just to show they know something when they are just empty headed idiots that some dumb investors gave money to control.

[keekee]

Buying back here now and weighing whether to list the DUMB MMs into the Wall of SHAMED Market Makers. Will decide soon.

[Viewmont]

https://ir.hoththerapeutics.com/

[Viewmont]

News! April 17, 2020 8:00 AM
Hoth Therapeutics Announces Additions to its Board of Directors
NEW YORK, April 17, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to its Board of Directors. The Company also announced the resignation of current board member, Mr. Anthony Hayes.

"Management is pleased to announce the addition of two experienced and successful leaders to our Board," said Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics. "I am confident that their experience in business management, financial reporting and capital markets will serve us well as we continue our growth and development. We look forward to leveraging their insights and experience."
Mr. Knie continued, "Anthony Hayes has been a trusted colleague and advisor for many years. On behalf of my fellow directors, the company's management team, and shareholders, I'd like to thank him for the significant contributions he made during his service on Hoth's Board, we wish him the best in his future endeavors."
Graig Springer assisted with product development and governance at Invesco U.S., an investment management company, and from December 2013 to May 2019, he served in various capacities at OppenheimerFunds, Inc., an investment management company acquired by Invesco U.S., including distribution compliance and product development. In addition, Mr. Springer served on the Sub-Adviser Oversight Committee at OppenheimerFunds, Inc. Mr. Springer earned his Juris Doctor from Fordham University School of Law and concentrated in corporate law. Mr. Springer was elected to serve as Notes & Articles Editor for the Fordham Journal of Corporate and Financial Law and was the founding member and Chair of Fordham's Committee on Diversity in Business Law. Mr. Springer earned his Bachelors of Arts from Columbia College and majored in English and Comparative Literature.
Since 2011, Mr. Linsley has served as the Vice President of Operations of CFO Oncall, Inc., a company that provides financial management and CFO services, and since 2010 he has served as the Managing Member of Flagship Advisory & Management Group, LLC, a management consulting firm. In addition, since 2019, Mr. Linsley has served as the Chief

[ttottip]

Technical indicators point to strong buy. Going higher today.

[ttottip]

We have 4 more postmarket hours.

[gmcdonald34]

nice move here towards the EOD . . .moving in on that $1 mark. . .

[ttottip]

The main objective for today.

[ttottip]

Touchdown $$$$$$$$$$$$$

[mclaxer5155]

Got out here didn’t look like she had legs. But I’ll keep watch

[mclaxer5155]

Never mind she is falling back

[mclaxer5155]

Got grabbed a started we’ll see if it break 1$ I’ll add more

[Dipbuyguy]

Looking great here!

[ttottip]

Soon green.

[mclaxer5155]

Time to reload?

[ttottip]

30,000 block @ $0.8 disappeared. It's going higher!

[mclaxer5155]

Trying to decide if she is ready for a bounce or not. I got out at 2.67 the other day

[ttottip]

To produce a coronavirus vaccine it will take, at least, more than a year and half. The battle against this invisible enemy has just started.

[ttottip]

It will bounce back over $1 today!

[Dipbuyguy]

Smart money buys here!

[EmptyBones]

I warned people to sell at 2.50 the other day... good entry now again for they need to sustain a 1.00 and above to keep there Nas status.. offering at 1.00 filled

[posilock]

I should of sold it when it was over 2 bucks the other day. I didnt see it until it was to late

[ttottip]

I think so. Great prices to buy!

[EmptyBones]

Great loading zone. Picked up 7500 shares

[Dipbuyguy]

Looking to add the bottom here. No doubt this will bounce back. Always does.

[posilock]

Nope its down!!

[georgie18]

AIKI...82...pre market low...

[Golden Cross]

Back on the upswing here...$AIKI

[Hokieman04]

Can we get back over 2 please lol

[Viewmont]

Yes! This was really fast. AIkido Pharma Inc. Announces Closing of $14.0 Million Registered Direct Offering.

Now that this offering is complete, and HOTH news/TV inteview, hopefully we'll see the price go upward and stay up.

April 15, 2020 9:13 AM

Dr. Mark Poznansky Co-Creator of VaxCelerate Appeared on MSNBC to Discuss COVID-19 Vaccines
Dr. Poznansky serves as both scientific founder and advisory board member of HaloVax, a joint venture between Hoth Therapeutics and Voltron Therapeutics
NEW YORK, April 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky, Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a guest on MSNBC's All In with Chris Hayes last night to discuss COVID-19 vaccines and can be viewed from the following link https://drive.google.com/file/d/1t75xOLeIoIqwHZC8BIhJrrRZl3f1Wqmt/view

[georgie18]

Reactionary bounces are usually like that...

[Viewmont]

https://drive.google.com/file/d/1t75xOLeIoIqwHZC8BIhJrrRZl3f1Wqmt/view

April 15, 2020 9:13 AM Dr. Mark Poznansky Co-Creator of VaxCelerate Appeared on MSNBC to Discuss COVID-19 Vaccines
Dr. Poznansky serves as both scientific founder and advisory board member of HaloVax, a joint venture between Hoth Therapeutics and Voltron Therapeutics

[Viewmont]

April 15, 2020 9:13 AM Dr. Mark Poznansky Co-Creator of VaxCelerate Appeared on MSNBC to Discuss COVID-19 Vaccines
Dr. Poznansky serves as both scientific founder and advisory board member of HaloVax, a joint venture between Hoth Therapeutics and Voltron Therapeutics
NEW YORK, April 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky, Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a guest on MSNBC's All In with Chris Hayes last night to discuss COVID-19 vaccines and can be viewed from the following link https://drive.google.com/file/d/1t75xOLeIoIqwHZC8BIhJrrRZl3f1Wqmt/view

VaxCelerate was co-created by Dr. Mark Poznansky, MD, PhD, and Dr. Jeffrey Gelfand, MD, at Massachusetts General Hospital (MGH). Dr. Poznansky is the Director of the Vaccine and Immunotherapy Center (VIC) and a Physician at Massachusetts General Hospital, as well as an Associate Professor of Medicine at Harvard Medical School. He serves as both scientific founder and scientific advisory board member of HaloVax, the joint venture entity that was recently formed, based upon Hoth's recent agreement with Voltron Therapeutics, Inc. to undertake preclinical studies for the development of vaccine prospects to prevent the Coronoavirus (COVID-19).
VaxCelerate is a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) to aid at risk patients of being infected with COVID-19. The VaxCelerate vaccine platform was developed as a means of rapidly generating and pre-clinically testing a new vaccine against specific pathogen targets. The technology which received Department of Defense (DoD) funding historically demonstrated proof of concept in Lassa Fever, an emerging infectious disease. HaloVax intends to use these same SAV principles to assist in the development of a potential vaccine against the COVID-19 pandemic.
Dr. Poznansky will help advise Halovax on the early clinical research and implementation of testing in the hospital setting.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
To learn more, please visit www.hoththerapeutics.com.
About HaloVax™, LLC
The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapeutics Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized cellular immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com.
About Voltron Therapeutics, Inc.
Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related). For more information please visit www.voltrontx.com
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the SAV technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
Contacts
Investor Relations Contact:
Phone: [phone]
Email: [e-mail]
www.hoththerapeutics.com
KCSA Strategic Communications
Valter Pinto, Managing Director
[phone]
[e-mail]

[Viewmont]

That was pretty fast!

[georgie18]

AIKI...88s clearing here off the 83 bounce...

[KILLERMIKE]

Lets see if this thing climbs back in the saddle.

[georgie18]

AIKI...83...added here...https://finance.yahoo.com/news/aikido-pharma-inc-announces-closing-174100561.html

Still bidding the open gap...

[aspirin]

Venus and Mars:

Whether one lost money or gained, it's a thing of beauty when you overlap HOTH chart with AIKI chart from yesterday and today.

[Dipbuyguy]

I love how fast this one can move!

[georgie18]

AIKI...85 bidding the open gap in the 72 range...

[jamesclopez00]

jumped in yesterday...

[BayTrader280]

$AIKI VOLUME VROOM VROOM!

[georgie18]

AIKI...93s clearing here...

[georgie18]

AIKI...23,700 buy @ .87...at the high of after hours trading...

[Bronk]

It’s showing some good support in the mid 80s.. so for now that’s a good sign. Everything will depend on tomorrow imo. If this can get back above 1, I think you’ll have a good shot at 1.75 or so.